Skip to content

Anistreplase Classification Essay

Classification essays rank the groups of objects according to a common standard. For example, popular inventions may be classified according to their significance to the humankind.

Classification is a convenient method of arranging data and simplifying complex notions.

When you select a topic, do not forget about the length of your paper. Choose the topic you will be able to cover in your essay, do not write about something global or general.

Consider these examples:

  • Evaluate the best to worst methods of upbringing.
  • Rate the films according to their influence on people.
  • Classify careers according to the opportunities they offer.

You should point out the common classifying principle for the group you are writing about. It will become the thesis of your essay.

It is important for you to use clear method of classification in your essay, especially when you are dealing with subjective categories such as "quality" or "benefit". Make sure you explain what you mean by this term.

To organize a classification essay, the writer should:

  • categorize each group.
  • describe or define each category. List down the general characteristics and discuss them.
  • provide enough illustrative examples. An example should be a typical representative of the group.
  • point out similarities or differences of each category, using comparison-contrast techniques.

1. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two-year experience with 250 patients. Am J Cardiol. 1967;20:457–64.[PubMed]

2. Goldberg RJ, Gore JM, Alpert JS, et al. Cardiogenic shock after acute myocardial infarction. Incidence and mortality from a community-wide perspective, 1975 to 1988. N Engl J Med. 1991;325:1117–22.[PubMed]

3. Bates ER, Moscucci M. Post-myocardial infarction cardiogenic shock. In: Brown DL, editor. Cardiac Intensive Care. Philadelphia: Pa: Saunders; 1998. pp. 215–27.

4. Hochman JS, Boland J, Sleeper LA, et al. Current spectrum of cardiogenic shock and effect of early revascularisation on mortality. Results of an international registry. SHOCK registry investigators. Circulation. 1995;91:873–81.[PubMed]

5. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341:625–34.[PubMed]

6. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340:1162–8.[PubMed]

7. Holmes DR Jr, Bates ER, Kleiman NS, et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol. 1995;26:668–74.[PubMed]

8. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the united states national registry of myocardial infarction. J Am Coll Cardiol. 1996;27:1321–6.[PubMed]

9. Menon V, Hochman JS. Management of cardiogenic shock complicating acute myocardial infarction. Heart. 2002;88:531–7.[PMC free article][PubMed]

10. Braunwald EB. Hemodynamic disturbances in acute myocardial infarction. In: Brainwald EB, editor. Heart disease. Philadelphia: W.B. Saunders; 1997. pp. 1233–45.

11. Forrester JS, Diamond G, Chatterjee K, Swan HJ. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (second of two parts) N Engl J Med. 1976;295:1404–13.[PubMed]

12. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) Lancet. 1986;1:397–402.[PubMed]

13. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. The International Study Group. Lancet. 1990;336:71–5.[PubMed]

14. ISIS-3: a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet. 1992;339:753–70.[PubMed]

15. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999. The national registry of myocardial infarct on 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–63.[PubMed]

16. Hochman JS, Buller CE, Dzavik V, et al. Cardiogenic shock complicating AMI etiologies, management and outcome-overall findings of the SHOCK trial registry. Circulation. 1998;98(Suppl 1):1–778.

17. Webb JG, Sleeper LA, Buller CE, et al. Implications of the timing of onset of cardiogenic shock after acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1084–90.[PubMed]

18. Tipoo FA, Quraishi AR, Najaf SM, et al. Outcome of cardiogenic shock complicating acute myocardial infarction. J Coll Physicians Surg Pak. 2004;14:6–9.[PubMed]

19. Carnendran L, Abboud R, Sleeper LA, et al. Trends in cardiogenic shock: report from the SHOCK study. Should we emergently revascularize Occluded Coronaries for cardiogenic shock? Eur Heart J. 2001;22:472–8.[PubMed]

20. Jacobs AK, French JK, Col J, et al. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1091–96.[PubMed]

21. Holmes DR Jr, Berger PB, Hochman JS, et al. Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. Circulation. 1999;100:2067–73.[PubMed]

22. Lindholm MG, Boesgaard S, Torp-Pedersen C, Kober L TRACE registry study group. Diabetes mellitus and cardiogenic shock in acute myocardial infarction. Eur J Heart Fail. 2005;7:834–9.[PubMed]

23. Hochman JS, Buller CE, Sleeper LA, et al. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1063–70.[PubMed]

24. Hochman J. Annual Scientific Sessions. Dallas, TX: American Heart Association; 1998. Cardiogenic shock.

25. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol. 1992;20:1482–9.[PubMed]

26. Sanborn TA, Sleeper LA, Webb JG, et al. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol. 2003;42:1373–9.[PubMed]

27. Hands ME, Rutherford JD, Muller JE, et al. The in-hospital development of cardiogenic shock after myocardial infarction: incidence, predictors of occurrence, outcome and prognostic factors. The MILIS Study Group. J Am Coll Cardiol. 1989;14:40–6.[PubMed]

28. Leor J, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: incidence, risk factors, and outcome. SPRINT Study Group. Am J Med. 1993;94:265–73.[PubMed]

29. Scheidt S, Ascheim R, Killip T 3rd. Shock after acute myocardial infarction. A clinical and hemodynamic profile. Am J Cardiol. 1970;26:556–64.[PubMed]

30. Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2000;35:136–43.[PubMed]

31. Fincke R, Hochman JS, Lowe AM, et al. SHOCK investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340–8.[PubMed]

32. Hollenberg SM, Kavinsky CJ, Parrillo JE. Cardiogenic Shock. Ann of Intern Med. 1999;131:47–59.[PubMed]

33. Menon V, White H, LeJemtel T, Webb JG, Sleeper LA, Hochman JS. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1071–6.[PubMed]

34. Hasdai D, Holmes DR Jr, Califf RM, et al. Cardiogenic shock complicating acute myocardial infarction: predictors of death. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO) Investigators. Am Heart J. 1999;138:21–31.[PubMed]

35. Duvernoy CS, Bates ER. Management of cardiogenic shock attributable to acute myocardial infarction in the reperfusion era. J Intensive Care Med. 2005;20:188–98.[PubMed]

36. Nishimura RA, Tajik AJ, Shub C, Miller FA Jr, Ilstrup DM, Harrison CE. Role of two-dimensional echocardiography in the prediction of in-hospital complications after acute myocardial infarction. J Am Coll Cardiol. 1984;4:1080–7.[PubMed]

37. Picard MH, Davidoff R, Sleeper L, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation. 2003;107:279–84.[PubMed]

38. Holmes DR Jr, Califf RM, Van de Werf F, et al. Difference in countries use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet. 1997;349:75–8.[PubMed]

39. Connors AF Jr, Speroff T, Dawson NV, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT investigators. JAMA. 1996;276:889–97.[PubMed]

40. Richard C, Ricome JL, Rimailho A, Bottineau G, Auzepy P. Combined hemodynamic effects of dopamine and dobutamine in cardiogenic shock. Circulation. 1983;67:620–6.[PubMed]

41. Gunnar RM, Bourdillon PD, Dixon DW, et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American college of cardiology/American Heart Association Task Force on Assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction) Circulation. 1990;82:664–707.[PubMed]

42. Kern MJ, Aguirre F, Bach R, Donohue T, Siegel R, Segal J. Augmentation of coronary blood flow by intra-aortic balloon pumping in patients after coronary angioplasty. Circulation. 1993;87:500–11.[PubMed]

43. Anderson RD, Ohman EM, Holmes DR Jr, et al. Use of intra-aortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global utilization of streptokinase and tpa for occluded coronary arteries. J Am Coll Cardiol. 1997;30:708–15.[PubMed]

44. Sanborn TA, Sleeper LA, Bates ER, et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1123–1129.[PubMed]

45. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the ACC/AHA Task Force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) Circulation. 2004;110:e82–292.[PubMed]

46. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian study of early thrombolysis (ASSET) Lancet. 1988;2:525–30.[PubMed]

47. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS trial study group. Lancet. 1990;335:427–31.[PubMed]

48. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. ISIS-2 (Second International Study of Infarct Survival) Collaborative group. Lancet. 1988;2:349–60.[PubMed]

49. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med. 1993;329:673–82.[PubMed]

50. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO angiographic investigators. N Engl J Med. 1993;329:1615–22.[PubMed]

51. Kennedy JW, Gensini GG, Timmis GC, Maynard C. Acute myocardial infarction treated with intracoronary streptokinase: a report of the society for cardiac angiography. Am J Cardiol. 1985;55:871–7.[PubMed]

52. Berger PB, Holmes DR Jr, Stebbins AL, Bates ER, Califf RM, Topol EJ. Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. An observational study. Circulation. 1997;96:122–7.[PubMed]

53. Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) multicenter trial of angioplasty for Shock-(S)MASH. Eur Heart J. 1999;20:1030–8.[PubMed]

54. Stauffer JC, Urban P, Bleed D, et al. Result of the “Swiss” multicenter evaluation of early angioplasty for shock following myocardial infarction. Circulation. 1997;96(Suppl 1):I–209.

55. Schindler DM, Palmeri ST, Antonelli TA, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol. 2000;36:1097–103.[PubMed]

56. Hochman JS, Sleeper LA, White HD, et al. SHOCK investigators. Should We emergently revascularise occluded coronaries for cardiogenic shock. One-year survival following early revascularization for cardiogenic shock. JAMA. 2001;285:190–2.[PubMed]

57. Barbash IM, Behar S, Battler A, et al. Management and outcome of cardiogenic shock complicating acute myocardial infarction in hospitals with and without on-site catheterization facilities. Heart. 2001;86:145–9.[PMC free article][PubMed]

58. Hochman JS, Gersh BJ. Acute myocardial infarction: complications. In: Topol EJ, editor. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven; 1998. pp. 437–80.

59. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The primary angioplasty in myocardial infarction study group. N Engl J Med. 1993;328:673–9.[PubMed]

60. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The global use of strategies to open occluded coronary arteries in acute coronary syndromes (GUSTO IIb) Angioplasty substudy investigators. N Engl J Med. 1997;336:1621–8.[PubMed]

61. O’Neill W, Erbel R, Laufer N, Walton J, Bates E, Topol E. Coronary angioplasty therapy of cardiogenic shock complicating acute myocardial infarction. Circulation. 1985;72:309.

62. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O’Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation. 1988;78:1345–51.[PubMed]

63. Landin RJ, Rothbaum DA, Linnemeier TJ, Ball MW. Hospital mortality of patients undergoing emergency angioplasty for acute myocardial infarction: relationship of mortality to cardiogenic shock and successful angioplasty. Circulation. 1988;78:II9.

64. Verna E, Repetto S, Boscarini M, Ghezzi I, Binaghi G. Emergency coronary angioplasty in patients with severe left ventricular dysfunction or cardiogenic shock after acute myocardial infarction. Eur Heart J. 1989;10:958–66.[PubMed]

65. Kaplan AJ, Bengtson JR, Aronson LG, et al. Reperfusion improves survival in patients with cardiogenic shock after myocardial infarction. J Am Coll Cardiol. 1990;15:155A.

66. Lee L, Erbel R, Brown TM, Laufer N, Meyer J, O’Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J Am Coll Cardiol. 1991;17:599–603.[PubMed]

67. Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol. 1992;19:647–53.[PubMed]

68. Moosvi AR, Khaja F, Villanueva L, Gheorghiade M, Douthat L, Goldstein S. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 1992;19:907–14.[PubMed]

69. Laney PL, Dell’Italia LJ, Brooks SR, et al. Follow-up exercise function in patients presenting with cardiogenic shock and acute transmural myocardial infarction. J Am Coll Cardiol. 1993;21:77A.

70. Eltchainoff H, Simpfendorfer C, Franco I, Raymond RE, Casale PN, Whitlow PL. Early and 1-year survival rates in acute myocardial infarction complicated by cardiogenic shock: a retrospective study comparing coronary angioplasty with medical treatment. Am Heart J. 1995;130:459–64.[PubMed]

71. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty therapy and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and long-term survival. J Am Coll Cardiol. 1998;31:294–300.[PubMed]

72. Webb JG, Carere RG, Hilton JD, et al. Usefulness of coronary stenting for cardiogenic shock. Am J Cardiol. 1997;79:81–4.[PubMed]

73. Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol. 2000;36:685–92.[PubMed]

74. Klein LW, Shaw RE, Krone RJ, et al. American College of Cardiology National Cardiovascular Data Registry. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol. 2005;96:35–41.[PubMed]

75. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations of the American College of Cardiology/American Heart Association Task Force on practice guidelines. (Committee on management of acute myocardial infarction) Circulation. 1999;100:1016–30.[PubMed]

76. DiSesa V, Patel M, Hollenberg SM. Coronary artery bypass grafting for cardiogenic shock. In: Hollenberg SM, Bates ER, editors. Cardiogenic shock. Armon, NY: Futura; 2002. pp. 103–17.

77. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the should we emergently revascularize occluded coronaries for cardiogenic shock (SHOCK) trial. Circulation. 2005;112:1992–2001.[PubMed]

78. Subramanian VA, Roberts AJ, Zema MJ, et al. Cardiogenic shock following acute myocardial infarction: late functional results after emergency cardiac surgery. NY State J Med. 1980;80:947–52.[PubMed]

79. Dunkman WB, Leinbach RC, Buckley MJ, et al. Clinical and hemodynamic results of intraaortic balloon pumping and surgery for cardiogenic shock. Circulation. 1972;46:465–77.[PubMed]

80. Laks H, Rosenkranz E, Buckberg GD. Surgical treatment of cardiogenic shock after myocardial infarction. Circulation. 1986;74:III11–6.